Reviva Pharmaceuticals Holdings, Inc. (RVPH)

The past six months have seen several events impacting RVPH's stock price, which has experienced a significant decline. Key events include a corporate presentation announcement, a regulatory setback when the FDA recommended a second Phase 3 trial, Q3 2025 results reporting a net loss, a Neuroscience 2025 presentation, the grant of a European patent, a proposed public offering of common stock and warrants, and Q2 2025 financial results.

Specific information regarding the demand seasonality for Reviva Pharmaceuticals Holdings, Inc.'s products and services is not explicitly detailed. There is a seasonal analysis available for RVPH stock, which suggests a "Buy Date of August 13 and a Sell Date of November 2" has historically resulted in a geometric average return of 49.67% above the S&P 500 Total Return Index over the past 6 years.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for unmet medical needs in central nervous system, respiratory, inflammatory, and cardiometabolic diseases. Its pipeline includes Brilaroxazine (RP5063), in clinical development for neuropsychiatric indications and showing nonclinical activity for inflammatory diseases, and RP1208, in preclinical development for depression and obesity. Brilaroxazine has completed a global Phase 2 clinical trial and a Phase 3 trial (RECOVER-1) for schizophrenia.

Reviva Pharmaceuticals Holdings, Inc. is headquartered in Cupertino, California, United States. The company strategically targets the United States and Europe, where there is substantial demand for advanced therapeutic solutions. Its clinical trials have been conducted across the U.S., Europe, and Asia.

Information specifically detailing Reviva Pharmaceuticals Holdings, Inc.'s brand reputation in the past year is not explicitly available. However, events that could influence reputation include positive scientific publications, regulatory setbacks, financial performance and offerings, and stock price performance.

Reviva Pharmaceuticals Holdings, Inc. has a mixed ownership structure, with institutional, retail, and individual investors. Approximately 63.18% of the stock is owned by institutional investors, with major holders including Diadema Partners Lp and Vanguard Group Inc. Individual ownership by insiders is approximately 0.09%, with Rahul Nayar listed as a major shareholder with 3.00% ownership.